Rivaroxaban

Rivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a

RIVAROXABAN DESMORPHOLINONE ANALOG

RIVAROXABAN DESTHIOPHENE ANALOG

RIVAROXABAN N-ACYL GLYCOLIC ACID

An orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM) that inhibits thrombin formation without prolonging bleeding time approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.

An orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM) that inhibits thrombin formation without prolonging bleeding time approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.

An orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM) that inhibits thrombin formation without prolonging bleeding time approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.

An orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM) that inhibits thrombin formation without prolonging bleeding time approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.